Pfizer's JAK Inhibitor Xeljanz Approved, Set to Launch in RA
Pfizer Inc. is wasting no time with the rollout of its Janus kinase (JAK) inhibitor tofacitinib, branded Xeljanz, which gained FDA approval late Tuesday for adults with moderate to severely active rheumatoid arthritis (RA).
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter